Try a new search

Format these results:

Searched for:

in-biosketch:true

person:newmaj05

Total Results:

135


ASSOCIATIONS BETWEEN CONVENTIONAL CARDIOVASCULAR RISK FACTORS AND RISK OF PERIOPERATIVE ACUTE MYOCARDIAL INFARCTION AFTER NON-CARDIAC SURGERY [Meeting Abstract]

Wilcox, Tanya; Smilowitz, Nathaniel; Newman, Jonathan; Berger, Jeffrey
ISI:000429659703516
ISSN: 0735-1097
CID: 3055252

MISSED OPPORTUNITIES FOR CARDIOVASCULAR DISEASE (CVD) PREVENTION DURING US AMBULATORY CARE VISITS FOR PATIENTS WITH DIABETES MELLITUS [Meeting Abstract]

Newman, Jonathan; Berger, Jeffrey; Ladapo, Joseph
ISI:000429659703495
ISSN: 0735-1097
CID: 3055272

PREDICTORS OF LDL-CHOLESTEROL AND SYSTOLIC BLOOD PRESSURE (SBP) GOAL ATTAINMENT AT ONE YEAR: INTERIM DATA FROM THE ISCHEMIA TRIAL [Meeting Abstract]

Newman, Jonathan D.; Alexander, Karen; O'Brien, Sean; Gu, Xiangqiong; Govindan, Sajeev; Senior, Roxy; Rezende, Paulo; Moorthy, Nagaraja; Demkow, Marcin; Lopez-Sendon, Jose; Bockeria, Olga; Gosselin, Gilbert; Pandit, Neeraj; Stone, Peter; Boden, William; Spertus, John; Stone, Gregg; Hochman, Judith; Maron, David
ISI:000429659700085
ISSN: 0735-1097
CID: 3055352

The 2017 high blood pressure clinical practice guideline: The old and the new [Editorial]

Schwartzbard, Arthur Z; Newman, Jonathan D; Weintraub, Howard S; Baum, Seth J
PMID: 29574983
ISSN: 1932-8737
CID: 3011172

Walking to a pathway for cardiovascular effects of air pollution

Thurston, George D; Newman, Jonathan D
PMID: 29221647
ISSN: 1474-547x
CID: 2835622

Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review

Mathew, Roy O; Schulman-Marcus, Joshua; Nichols, Elizabeth L; Newman, Jonathan D; Bangalore, Sripal; Farkouh, Michael; Sidhu, Mandeep S
Chelation therapy, typically used to remove heavy metal toxins, has also been controversially used as a treatment for coronary artery disease. The first Trial to Assess Chelation Therapy (TACT) aimed to provide evidence on chelation therapy's potential for benefit or harm. Although TACT had some significant results, the trial does not provide enough evidence to recommend routine chelation therapy and has limitations. The second TACT was recently funded reigniting a discussion about the value of chelation therapy, its efficacy, and allocation of research resources. Despite limited evidence, patients continue to pursue chelation therapy as a treatment for coronary artery disease. As the medical community has a responsibility to understand all treatments patients pursue, it is important to comprehensively appraise chelation therapy for cardiovascular disease. Understanding the background of heavy metal toxicity, the putative target of chelation therapy, on the cardiovascular system is important to contextualize the role of chelation therapy in cardiovascular disease prevention. We review the clinical evidence of heavy metal toxicity and cardiovascular disease, and available clinical trial data on use of chelation therapy to minimize the cardiovascular burden of heavy metal toxicity.
PMID: 29129003
ISSN: 1573-7241
CID: 2785412

The Effect of a Vegan versus AHA DiEt in Coronary Artery Disease (EVADE CAD) trial: study design and rationale

Shah, Binita; Ganguzza, Lisa; Slater, James; Newman, Jonathan D; Allen, Nicole; Fisher, Edward; Larigakis, John; Ujueta, Francisco; Gianos, Eugenia; Guo, Yu; Woolf, Kathleen
Background/UNASSIGNED:Multiple studies demonstrate the benefit of a vegan diet on cardiovascular risk factors when compared to no intervention or usual dietary patterns. The aim of this study is to evaluate the effect of a vegan diet versus the American Heart Association (AHA)-recommended diet on inflammatory and glucometabolic profiles in patients with angiographically defined coronary artery disease (CAD). Study Design/UNASSIGNED:This study is a randomized, open label, blinded end-point trial of 100 patients with CAD as defined by ≥50% diameter stenosis in a coronary artery ≥2 mm in diameter on invasive angiography. Participants are randomized to 8 weeks of either a vegan or AHA-recommended diet (March 2014 and February 2017). Participants are provided weekly groceries that adhere to the guidelines of their diet. The primary endpoint is high sensitivity C-reactive concentrations. Secondary endpoints include anthropometric data, other markers of inflammation, lipid parameters, glycemic markers, endothelial function, quality of life data, and assessment of physical activity. Endpoints are measured at each visit (baseline, 4 weeks, and 8 weeks). Dietary adherence is measured by two weekly 24-hour dietary recalls, a 4-day food record during the week prior to each visit, and both plasma and urine levels of trimethylamine-N-oxide at each visit. Conclusion/UNASSIGNED:This study is the first to comprehensively assess multiple indices of inflammation and glucometabolic profile in a rigorously conducted randomized trial of patients with CAD on a vegan versus AHA-recommended diet.
PMCID:5764176
PMID: 29333503
ISSN: 2451-8654
CID: 2908222

Primary Prevention of Cardiovascular Disease in Diabetes Mellitus

Newman, Jonathan D; Schwartzbard, Arthur Z; Weintraub, Howard S; Goldberg, Ira J; Berger, Jeffrey S
Type 2 diabetes mellitus (T2D) is a major risk factor for cardiovascular disease (CVD), the most common cause of death in T2D. Yet, <50% of U.S. adults with T2D meet recommended guidelines for CVD prevention. The burden of T2D is increasing: by 2050, approximately 1 in 3 U.S. individuals may have T2D, and patients with T2D will comprise an increasingly large proportion of the CVD population. The authors believe it is imperative that we expand the use of therapies proven to reduce CVD risk in patients with T2D. The authors summarize evidence and guidelines for lifestyle (exercise, nutrition, and weight management) and CVD risk factor (blood pressure, cholesterol and blood lipids, glycemic control, and the use of aspirin) management for the prevention of CVD among patients with T2D. The authors believe appropriate lifestyle and CVD risk factor management has the potential to significantly reduce the burden of CVD among patients with T2D.
PMCID:5656394
PMID: 28797359
ISSN: 1558-3597
CID: 2664152

Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1beta Pathway in Systemic Lupus Erythematosus

Nhek, Sokha; Clancy, Robert; Lee, Kristen A; Allen, Nicole M; Barrett, Tessa J; Marcantoni, Emanuela; Nwaukoni, Janet; Rasmussen, Sara; Rubin, Maya; Newman, Jonathan D; Buyon, Jill P; Berger, Jeffrey S
OBJECTIVE: Systemic lupus erythematosus (SLE) is associated with the premature development of cardiovascular disease. The platelet-endothelium interaction is important in the pathogenesis of cardiovascular disease. In this study, we investigated the platelet phenotype from patients with SLE and matched controls, and their effect on endothelial cells. APPROACH AND RESULTS: Platelet aggregability was measured in 54 SLE subjects off antiplatelet therapy (mean age 40.1+/-12.8 years; 82% female; 37% white) with age- and sex-matched controls. Platelets were coincubated with human umbilical vein endothelial cells (HUVECs) and changes to gene expression assessed by an RNA array and quantitative reverse transcription polymerase chain reaction. SLE disease activity index ranged from 0 to 22 (mean 5.1+/-3.9). Compared with controls, patients with SLE had significantly increased monocyte and leukocyte-platelet aggregation and platelet aggregation in response to submaximal agonist stimulation. An agnostic microarray of HUVECs cocultured with SLE platelets found a platelet-mediated effect on endothelial gene pathways involved in cell activation. Sera from SLE versus control subjects significantly increased (1) activation of control platelets; (2) platelet adhesion to HUVECs; (3) platelet-induced HUVEC gene expression of interleukin-8, and ICAM-1; and (4) proinflammatory gene expression in HUVECs, mediated by interleukin-1beta-dependent pathway. Incubation of SLE-activated platelets with an interleukin-1beta-neutralizing antibody or HUVECs pretreated with interleukin-1 receptor antibodies attenuated the platelet-mediated activation of endothelial cells. CONCLUSIONS: Platelet activity measurements and subsequent interleukin-1beta-dependent activation of the endothelium are increased in subjects with SLE. Platelet-endothelial interactions may play a role in the pathogenesis of cardiovascular disease in patients with SLE.
PMCID:5597960
PMID: 28153882
ISSN: 1524-4636
CID: 2437182

Hyperglycemia enhances arsenic-induced platelet and megakaryocyte activation

Newman, Jonathan D; Echagarruga, Christina T; Ogando, Yoscar M; Montenont, Emilie; Chen, Yu; Fisher, Edward A; Berger, Jeffrey S
OBJECTIVE: Low to moderate inorganic arsenic (iAs) exposure is independently associated with cardiovascular disease (CVD), particularly for patients with diabetes mellitus (DM). The mechanism of increased CVD risk from iAs exposure in DM has not been adequately characterized. We evaluated whether increasing concentrations of glucose enhance the effects of iAs on platelet and megakaryocyte activity, key steps in atherothrombosis. METHODS: Healthy donor whole blood was prepared in a standard fashion and incubated with sodium arsenite in a range from 0 to 10 microM. iAs-induced platelet activation was assessed by platelet receptor CD62P (P-selectin) expression and monocyte-platelet and leukocyte-platelet aggregation (MPA and LPA, respectively) in the presence of increasing sodium arsenite and glucose concentrations. Megakaryocyte (Meg-01) cell adhesion and gene expression was assessed after incubation with or without iAs and increasing concentrations of D-glucose. RESULTS: Platelet activity markers increased significantly with 10 vs. 0 microM iAs (P < 0.05 for all) and with higher D-glucose concentrations. Platelet activity increased significantly following co incubation of 1 and 5 microM iAs concentrations with hyperglycemic D-glucose (P < 0.01 for both) but not after incubation with euglycemic D-glucose. Megakaryocyte adhesion was more pronounced after co incubation with iAs and hyperglycemic than euglycemic D-glucose, while gene expression increased significantly to iAs only after co incubation with hyperglycemic D-glucose. CONCLUSION: We demonstrate that glucose concentrations common in DM potentiate the effect of inorganic arsenic exposure on markers of platelet and megakaryocyte activity. Our results support recent observational cohort data that DM enhances the vasculotoxic effects of arsenic exposure, and suggest that activation of the platelet-megakaryocyte hemostatic axis is a pathway through which inorganic arsenic confers atherothrombotic risk, particularly for patients with DM.
PMCID:5338098
PMID: 28264687
ISSN: 1479-5876
CID: 2476162